Get in touch with us
Get in touch with us
Have questions, feedback, or need assistance? Our team is here to help you.
Have questions, feedback, or need assistance? Our team is here to help you.
FAQs
Answers to Your Most Common Questions
Everything you need to know about getting started, using the platform, and unlocking its full potential.
What problem does Revilico solve?
Drug discovery today is fragmented and inefficient. Scientists juggle massive datasets, multiple tools, and manual workflows slowing innovation. Revilico unifies these tools under one OS, allowing for centralized data, guided AI agents, and seamless wet-lab translation
Why is now the right time for this technology?
Pharma is undergoing a radical digital transformation. With 40% of patents expiring by 2030 and $180B in revenue at risk, companies are under pressure to innovate. Revilico’s timing coincides with advancements in AI, cloud computing, and multi-omics integration enabling unprecedented efficiency and discovery potential
How does the Revilico platform work?
The OS integrates core engines Docking, Co-folding, Molecular Dynamics (MD), FEP+, Generative and Quantum Chemistry, and Virtual Cells, to cover the full spectrum of drug discovery, from Target ID to Preclinical Development
What makes Revilico different from traditional tools?
Unlike fragmented computational pipelines, Revilico unifies centralized multi-omic datasets, AI-driven workflow automation, GPU-accelerated algorithms that run 70× faster than traditional docking, and integrated wet-lab validation with virtual cell simulations.
What is “Virtual Cell”?
Virtual Cell is an AI co-pilot for wet-lab screening. It simulates cellular pathways and predicts drug-cell interactions. helping researchers identify promising compounds early and reduce costly lab experiments. We use both data driven techniques and physics based pathway propagation models to predict perturbed phenotypes.
What is Revilico's "Data Ecosystem"?
Revilico’s proprietary data infrastructure harmonizes 330M single cells, 70B+ compounds, 246M+ proteins, 47M+ articles, and 464k clinical trials into a structured database. It unifies fragmented public and proprietary data into one interoperable ecosystem, driving faster and smarter drug design.
How has Revilico been validated?
Read more about specific case studies we have run on our resources page. Revilico’s predictions and experimental bioactivities show high correlation across multiple targets. The company has validated compounds across several cancer targets and co-developed pipelines in oncology, immunology, and CNS indications
How does Revilico ensure accuracy?
Computational tools are a powerful resource to help test, validate, and explore hypotheses exceptionally quickly to cut down on experimental waste. Before moving forward with experimentation, we always calibrate our algorithms for your system to ensure you choose the right algorithm suitable for your systems.
What results has Revilico achieved?
Revilico achieves a 3× higher hit rate (80–90% vs. 30–50%) for target validation, reduces compound screening by over 98% with a nearly 5% hit rate, accelerates DMTA cycles by 75–83%, and lowers IND costs by 60–75% (from $27M to $7–10M).
How does Revilico compare to competitors?
Revilico offers a true end-to-end OS with Virtual Cells, multi-omic integration, quantum chemistry, and robotic automation, capabilities competitors treat as separate modules. It democratizes access with a user-friendly, cloud-scaled interface.
How do I get started?
Just click Join Now and sign up for an account. Revilico provides white-glove onboarding, personalized setup, and guided training to help you get started immediately, or you can book a meeting with our team for a tailored walkthrough.
What happens after I get an account?
Revilico offers comprehensive training, detailed documentation, and ongoing support resources to help every user quickly learn, build, and scale their projects with confidence. We believe that a large part of the process is teaching those using the tools how to interpret, calibrate, and gain intuition on the simulations.
FAQs
Answers to Your Most Common Questions
Everything you need to know about getting started, using the platform, and unlocking its full potential.
What problem does Revilico solve?
Drug discovery today is fragmented and inefficient. Scientists juggle massive datasets, multiple tools, and manual workflows slowing innovation. Revilico unifies these tools under one OS, allowing for centralized data, guided AI agents, and seamless wet-lab translation
Why is now the right time for this technology?
Pharma is undergoing a radical digital transformation. With 40% of patents expiring by 2030 and $180B in revenue at risk, companies are under pressure to innovate. Revilico’s timing coincides with advancements in AI, cloud computing, and multi-omics integration enabling unprecedented efficiency and discovery potential
How does the Revilico platform work?
The OS integrates core engines Docking, Co-folding, Molecular Dynamics (MD), FEP+, Generative and Quantum Chemistry, and Virtual Cells, to cover the full spectrum of drug discovery, from Target ID to Preclinical Development
What makes Revilico different from traditional tools?
Unlike fragmented computational pipelines, Revilico unifies centralized multi-omic datasets, AI-driven workflow automation, GPU-accelerated algorithms that run 70× faster than traditional docking, and integrated wet-lab validation with virtual cell simulations.
What is “Virtual Cell”?
Virtual Cell is an AI co-pilot for wet-lab screening. It simulates cellular pathways and predicts drug-cell interactions. helping researchers identify promising compounds early and reduce costly lab experiments. We use both data driven techniques and physics based pathway propagation models to predict perturbed phenotypes.
What is Revilico's "Data Ecosystem"?
Revilico’s proprietary data infrastructure harmonizes 330M single cells, 70B+ compounds, 246M+ proteins, 47M+ articles, and 464k clinical trials into a structured database. It unifies fragmented public and proprietary data into one interoperable ecosystem, driving faster and smarter drug design.
How has Revilico been validated?
Read more about specific case studies we have run on our resources page. Revilico’s predictions and experimental bioactivities show high correlation across multiple targets. The company has validated compounds across several cancer targets and co-developed pipelines in oncology, immunology, and CNS indications
How does Revilico ensure accuracy?
Computational tools are a powerful resource to help test, validate, and explore hypotheses exceptionally quickly to cut down on experimental waste. Before moving forward with experimentation, we always calibrate our algorithms for your system to ensure you choose the right algorithm suitable for your systems.
What results has Revilico achieved?
Revilico achieves a 3× higher hit rate (80–90% vs. 30–50%) for target validation, reduces compound screening by over 98% with a nearly 5% hit rate, accelerates DMTA cycles by 75–83%, and lowers IND costs by 60–75% (from $27M to $7–10M).
How does Revilico compare to competitors?
Revilico offers a true end-to-end OS with Virtual Cells, multi-omic integration, quantum chemistry, and robotic automation, capabilities competitors treat as separate modules. It democratizes access with a user-friendly, cloud-scaled interface.
How do I get started?
Just click Join Now and sign up for an account. Revilico provides white-glove onboarding, personalized setup, and guided training to help you get started immediately, or you can book a meeting with our team for a tailored walkthrough.
What happens after I get an account?
Revilico offers comprehensive training, detailed documentation, and ongoing support resources to help every user quickly learn, build, and scale their projects with confidence. We believe that a large part of the process is teaching those using the tools how to interpret, calibrate, and gain intuition on the simulations.
The Final Operating System of Pharma.
The Final Operating System of Pharma.